Discover the top 25 companies transforming the immunotherapy drugs market, including Merck & Co., Inc., Johnson & Johnson Services, Inc., F. Hoffmann-La Roche Ltd., and other industry leaders. Backed by a market projected to grow from $285.3B to $580.6B by 2029 at a CAGR of 15.3%, this analysis highlights competitive strengths, breakthrough innovations, and strategic moves shaping the future of the industry. Access the full market research report for deeper insights.

Download PDF Brochure:“Click Here”

Spotlights on the Industry’s Top Immunotherapy Drugs Companies

Merck & Co., Inc.

Merck & Co., Inc. is a global leader in the immunotherapy drugs market, primarily driven by its blockbuster PD-1 inhibitor, Keytruda, which accounted for 46% of its 2024 revenue. The company is actively diversifying its oncology portfolio to counter upcoming biosimilar competition by developing next-generation assets, such as the PD-1/VEGF bispecific antibody MK-2010. Merck’s strategic focus remains on expanding its immuno-oncology backbone through combination therapies and breakthrough science in tissue and precision molecular targeting.

Johnson & Johnson Services, Inc.

Johnson & Johnson maintains a significant presence in the oncology sector, with cancer treatments comprising approximately 27% of its total revenue. The company is pioneering the “Interventional Oncology” (INTO) initiative, which focuses on intratumoral treatments designed to deliver therapies directly into tumors to minimize systemic toxicity and enhance efficacy. Its portfolio includes established blockbusters like Darzalex alongside a robust pipeline of new therapies including CAR-T cell treatments and bispecific antibodies such as Rybrevant.

F. Hoffmann-La Roche Ltd.

Roche is a dominant player in the immunotherapy space, utilizing its dual expertise in pharmaceuticals and diagnostics to drive growth. To mitigate the impact of biosimilar erosion on legacy products like Rituxan and Herceptin, Roche has successfully transitioned to next-generation therapies including Phesgo, Hemlibra, and the eye disease treatment Vabysmo. The company continues to invest heavily in novel antibody-drug conjugates and combination therapies to maintain its competitive advantage in severe disease markets.

AstraZeneca

AstraZeneca has established itself as a major force in oncology, with the segment accounting for roughly 44% of its total revenue. The company’s immunotherapy strategy centers on multispecific antibodies, immune cell engagers, and antibody-drug conjugates (ADCs) to overcome tumor resistance. With a massive pipeline of nearly 200 projects, AstraZeneca is advancing several bispecific and trispecific T-cell engagers designed to generate synthetic immune responses in patients with weak anti-tumor profiles.

Pfizer Inc.

Pfizer holds a formidable position in the oncology market, further strengthened by its 2023 acquisition of Seagen, which added high-value antibody-drug conjugates (ADCs) like Padcev and Adcetris to its portfolio. The company’s oncology sales represent about 27% of its total revenue, supported by a diverse range of modalities including small molecules and immuno-oncology biologics. Pfizer is currently advancing clinical trials for dual PD-1/VEGF inhibitors and next-generation candidates such as sasanlimab and vepdegestrant.

Amgen Inc.

Amgen is a key contributor to the global immunotherapy landscape, focusing on innovative biologic therapies to treat cancer and other serious illnesses. The company leverages its long-standing expertise in human genetics and molecular biology to develop targeted treatments. Amgen’s strategic initiatives often involve the development of bispecific T-cell engagers (BiTE) and other immune-modulating platforms aimed at providing durable clinical responses for patients with hematological and solid tumors.

Novartis AG

Novartis is a pioneer in the field of advanced therapy medicinal products, particularly noted for its leadership in CAR-T cell therapy. The company maintains a strong focus on oncology and immunology, developing a range of monoclonal antibodies and targeted therapies. Novartis continues to invest in precision medicine and platform technologies to address unmet medical needs in various disease areas, including aggressive lymphomas and rare genetic disorders.

Eli Lilly and Company

Eli Lilly and Company has expanded its footprint in the immunotherapy market through significant investments in oncology and autoimmune disease research. The company utilizes advanced biotechnology platforms to discover and develop monoclonal antibodies and other immune-modulating agents. Lilly’s portfolio is characterized by a mix of established products and a growing pipeline of targeted therapies designed to improve survival outcomes and quality of life for patients with diverse cancer types.

Sanofi

Sanofi is a major global healthcare provider with a strong emphasis on immunology and inflammation. The company has focused its R\&D efforts on developing first-in-class or best-in-class immunotherapies for various indications, including oncology and respiratory diseases. Sanofi’s strategy involves leveraging strategic collaborations and innovative platforms to accelerate the delivery of transformative medicines that modulate the immune system to fight chronic and life-threatening conditions.

Bristol-Myers Squibb Company

Bristol-Myers Squibb (BMS) is a cornerstone of the immuno-oncology market, largely due to its pioneering PD-L1 inhibitor, Opdivo, which contributes significantly to its annual revenue. The company maintains a broad portfolio that spans multiple therapeutic areas, including hematology and immunology. BMS is focused on maintaining its leadership through the development of next-generation checkpoint inhibitors, cell therapies, and strategic acquisitions to broaden its clinical pipeline.

Gilead Sciences, Inc.

Gilead Sciences has established a significant presence in the immunotherapy market, particularly through its Kite Pharma subsidiary, which focuses on cell therapy. The company is a leader in CAR-T cell treatments for various blood cancers. Beyond cell therapy, Gilead is expanding its oncology portfolio through the development of monoclonal antibodies and small molecules, aiming to build a diversified business that complements its historical strength in antiviral medications.

Takeda Pharmaceutical Company Limited

Takeda is a global, values-based R\&D-driven biopharmaceutical leader with a strong commitment to oncology. The company’s immunotherapy efforts include the development of cell therapies and immune-modulating agents targeted at hematologic malignancies and solid tumors. Takeda actively participates in investigator-sponsored research and collaborative partnerships to explore novel mechanisms of action and improve treatment paradigms for patients with hard-to-treat cancers.

Teva Pharmaceutical Industries Ltd.

Teva Pharmaceutical Industries is a major player in the global pharmaceutical market, with a focus on both generic and specialty medicines. In the immunotherapy space, Teva is increasingly involved in the development and commercialization of biosimilars, which provide more affordable access to complex biologic treatments. The company also pursues innovative specialty assets to address specific needs in oncology and other therapeutic areas, balancing its portfolio between value-driven generics and high-growth biologics.

AbbVie Inc.

AbbVie is a leader in the global immunology market, driven by its heritage in treating autoimmune and inflammatory diseases. The company has aggressively expanded into oncology, focusing on hematological malignancies and solid tumors through the development of targeted therapies and immunotherapies. AbbVie’s strategy emphasizes late-stage clinical development and strategic acquisitions to sustain its growth as its foundational products face biosimilar competition.

GSK PLC

GSK is a global biopharma company with a strategic focus on the science of the immune system, human genetics, and advanced technologies. Its oncology and immunology pipelines are built around revolutionary platforms, including vaccines and specialized antibodies. GSK is particularly active in developing treatments for infectious diseases and respiratory conditions, while also advancing a portfolio of targeted cancer therapies designed to deliver tailored immune protection.

Immunocore Holdings PLC

Immunocore is a commercial-stage biotechnology company pioneering the development of a novel class of T-cell receptor (TCR) bispecific immunotherapies called ImmTAX. These therapies are designed to treat a wide range of diseases, including cancer, autoimmune, and infectious diseases. The company’s lead product targets previously unreachable intracellular antigens, representing a significant technological leap in the precision and scope of immunotherapy.

Astellas Pharma Inc.

Astellas Pharma is a global pharmaceutical company dedicated to improving health through innovative and reliable pharmaceutical products. In the immunotherapy sector, Astellas is notable for its collaborative work on antibody-drug conjugates (ADCs) like Padcev, developed in partnership with Pfizer. The company focuses on “Focus Areas” such as immuno-oncology and cell therapy, aiming to create new value by combining its internal expertise with external scientific advancements.

Genmab A/S

Genmab is an international biotechnology company specializing in the creation and development of differentiated antibody therapeutics for the treatment of cancer. The company has developed several proprietary technologies, such as DuoBody and HexaBody, which enable the design of bispecific and enhanced monoclonal antibodies. Genmab’s innovative pipeline and successful partnerships with major pharmaceutical firms have made it a key contributor to the evolution of antibody-based immunotherapies.

MacroGenics, Inc.

MacroGenics is a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer. The company utilizes its proprietary suite of next-generation antibody technologies, including its DART (Dual-Affinity Re-Targeting) platform, to create multispecific molecules. MacroGenics aims to harness the power of the immune system to provide more effective treatments for patients with various malignant diseases.

Ferring BV

Ferring Pharmaceuticals is a research-driven, specialty biopharmaceutical group active in global markets. While traditionally known for its work in reproductive medicine and gastroenterology, Ferring has expanded into the uro-oncology space with innovative gene therapy and immunotherapy approaches. The company focuses on niche areas where it can provide significant therapeutic benefits, often employing novel delivery mechanisms and biologic platforms to improve patient outcomes.

Y-mAbs Therapeutics, Inc.

Y-mAbs is a commercial-stage biopharmaceutical company focused on the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer. The company has a specialized focus on pediatric oncology and rare cancers, utilizing its proprietary antibody platforms to target specific tumor antigens. Y-mAbs aims to address significant unmet medical needs by providing targeted, high-affinity treatments for patients with limited options.

Biogen

Biogen is a pioneer in neuroscience, but it also maintains a strategic interest in immunology and specialized therapeutic areas. The company’s expertise in biologic manufacturing and protein engineering supports its efforts in developing treatments for autoimmune and neuro-inflammatory conditions. Biogen continues to explore how modulating the immune system can provide therapeutic benefits for complex diseases of the central nervous system and beyond.

Kyowa Kirin Co., Ltd.

Kyowa Kirin is a Japan-based global specialty pharmaceutical company that applies cutting-edge biotechnology to discover and deliver novel medicines. The company’s core strengths lie in antibody engineering, which it uses to develop immunotherapies for oncology, nephrology, and immunology. Kyowa Kirin’s commitment to “life-changing value” is reflected in its pipeline of unique monoclonal antibodies designed to target specific disease pathways with high precision.

Swedish Orphan Biovitrum AB (Sobi)

Sobi is a specialized international biopharmaceutical company focused on rare diseases. In the immunotherapy drugs market, Sobi provides innovative treatments for inflammation and genetic diseases, often acting as a bridge between specialized research and patient access in global markets. The company’s portfolio includes biologic agents that modulate the immune response to treat rare auto-inflammatory conditions and other specialized medical needs.

Boehringer Ingelheim International GmbH

Boehringer Ingelheim is one of the world’s largest private pharmaceutical companies, with a strong emphasis on research and development. In the oncology and immunology sectors, the company is advancing a diverse pipeline of cancer cell-directed and immune-based therapies. Boehringer Ingelheim focuses on areas of high unmet need, such as lung and gastrointestinal cancers, utilizing innovative modalities like T-cell engagers and cancer vaccines to improve patient survival and well-being.

Download PDF Brochure:“Click Here”